Healthcare stocks experienced a downturn in the afternoon session due to negative developments, including managed care providers seeing declines from an analyst downgrade and a lost lawsuit regarding Medicare bonus payments. Pharmaceutical and biotech companies also suffered drops, with Sarepta Therapeutics and GSK facing unfavorable news. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans, contributed to the downward pressure. Among impacted stocks, Revvity (RVTY) saw a significant move, reflecting market perception amid recent news and global trade negotiations. Despite the downturn, opportunities may arise for savvy investors in high-quality stocks.

Read more at Stockstory.org – Barron’s: Thermo Fisher, Exact Sciences, Integer Holdings, Revvity, and 10x Genomics Shares Are Falling, What You Need To Know